title: Challenges in Oral Lipid-lowering Therapy: Position Document of the Spanish Society of Cardiology.
abstract: Lipid-lowering therapy is one of the cornerstones of cardiovascular prevention and is one of the most effective strategies in the secondary prevention of ischemic heart disease. Nevertheless, the current treatment of lipid disorders, together with lifestyle changes, fails to achieve the targets recommended in clinical guidelines in a substantial proportion of patients. PCSK9 inhibitors have demonstrated safety and efficacy in the treatment of dyslipidemia. Due to their ability to reduce low-density lipoprotein cholesterol levels, these drugs have recently been approved for clinical use by Spanish regulatory agencies, with the aim of reducing cardiovascular risk in selected patient groups.
authors.affiliation: Servicio de Cardiología, Hospital Universitario Reina Sofía, Córdoba, Spain.
authors.forename: Manuel
authors.initials: M
authors.lastname: Anguita Sánchez
authors.affiliation: Servicio de Cardiología, Hospital Universitario La Paz, Madrid, Spain.
authors.forename: Almudena
authors.initials: A
authors.lastname: Castro Conde
authors.affiliation: Servicio de Cardiología, Hospital Universitario de San Juan, San Juan de Alicante, Alicante, Spain.
authors.forename: Alberto
authors.initials: A
authors.lastname: Cordero Fort
authors.affiliation: Servicio de Cardiología, Hospital de la Santa Creu y Sant Pau, Barcelona, Spain.
authors.forename: Xavier
authors.initials: X
authors.lastname: García-Moll Marimón
authors.affiliation: Servicio de Cardiología, Hospital Universitario de Málaga, Málaga, Spain.
authors.forename: Juan José
authors.initials: JJ
authors.lastname: Gómez Doblas
authors.affiliation: Servicio de Cardiología, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, A Coruña, Spain. Electronic address: jose.ramon.gonzalez.juanatey@sergas.es.
authors.forename: José R
authors.initials: JR
authors.lastname: González-Juanatey
authors.affiliation: Servicio de Cardiología, Hospital Universitario Vall d'Hebron, Barcelona, Spain.
authors.forename: Rosa María
authors.initials: RM
authors.lastname: Lidón Corbi
authors.affiliation: Servicio de Cardiología, Hospital Universitario La Paz, Madrid, Spain.
authors.forename: José Luis
authors.initials: JL
authors.lastname: López-Sendón
authors.affiliation: Servicio de Cardiología, Hospital Carlos III, Madrid, Spain.
authors.forename: José
authors.initials: J
authors.lastname: Mostaza Prieto
authors.affiliation: Servicio de Cardiología, Hospital Virgen de la Salud, Toledo, Spain.
authors.forename: Luis
authors.initials: L
authors.lastname: Rodríguez Padial
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D002309:Cardiology; D008078:Cholesterol, LDL / Q000097:blood; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy*; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D000091362:PCSK9 Inhibitors; D010347:Patient Care Planning; D011322:Primary Prevention; D055502:Secondary Prevention; D012955:Societies, Medical; D013030:Spain; D000071449:Proprotein Convertase 9
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D000091362:PCSK9 Inhibitors; C472125:PCSK9 protein, human; D000071449:Proprotein Convertase 9; C577155:evolocumab; C571059:alirocumab
keywords: Consensus document; Documento de consenso; Inhibidores PCSK9; Lipids and ischemic heart disease; Lípidos en enfermedad coronaria; PCSK9 inhibitors